Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZN-2208 in previously treated metastatic breast cancer
NCT01036113Phase 2Terminated
- Sponsor
- Enzon Pharmaceuticals
- Start
- Nov 2009
- Primary completion
- Feb 2012
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of firtecan pegol in breast cancer, sponsored by Enzon Pharmaceuticals. Started Nov 2009; status: terminated.
02
Drugs
firtecan pegol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01036113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01036113.